Urinary Proteomics to Guide Early Intervention to Prevent Complications in Type 2 Diabetes - a Feasibility Study

NCT06954090 · clinicaltrials.gov ↗

PHASE4

Phase

ENROLLING_BY_INVITATION

Status

50

Enrollment

OTHER

Sponsor class

Conditions

Type 2 DM
Type 2 DM /Diabetic Nephropathy
Albuminuria

Interventions

DRUG: Semaglutide, 1.34 mg/mL
DRUG: Finerenone Oral Tablet
DRUG: Dapagliflozin (DAPA)

Sponsor

Steno Diabetes Center Copenhagen

Collaborators

[object Object]